[{"id":"463320b9-dcd9-425e-8150-4f5633d6ec28","acronym":"TX05-03","url":"https://clinicaltrials.gov/study/NCT03556358","created_at":"2021-01-18T17:30:19.836Z","updated_at":"2024-07-02T16:36:18.414Z","phase":"Phase 3","brief_title":"Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer","source_id_and_acronym":"NCT03556358 - TX05-03","lead_sponsor":"Tanvex BioPharma USA, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • cyclophosphamide • epirubicin • TX05 (trastuzumab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 809","initiation":"Initiation: 06/28/2018","start_date":" 06/28/2018","primary_txt":" Primary completion: 11/27/2020","primary_completion_date":" 11/27/2020","study_txt":" Completion: 02/04/2021","study_completion_date":" 02/04/2021","last_update_posted":"2022-01-14"}]